INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Bellerophon Therapeutics, Inc. (“Bellerophon” or the “Company”) (NASDAQ: BLPH) concerning the Company and its officers’ possible violations of federal securities laws.

Bellerophon is a clinical-stage therapeutics company that focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.

On February 13, 2015, Bellerophon sold 13 million shares of stock in its initial public stock offering (the "IPO"). Since the IPO however, shares of Bellerophon stock have fallen sharply, after the Company reported poor operating results and certain executive changes.

If you purchased Bellerophon securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], toll-free at [phone], or by email to [e-mail], or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005701/en/

Law Offices of Howard G. SmithHoward G. Smith, [e-mail]